
## Maria Sandovici

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4698025/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of immune checkpoint inhibitor-induced polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2022, 81, e263-e263.	0.9	10
2	Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2022, 81, e210-e210.	0.9	13
3	Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica. Rheumatology, 2022, 61, 1072-1082.	1.9	29
4	Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open, 2022, 8, e001652.	3.8	6
5	Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica. Arthritis Research and Therapy, 2022, 24, 65.	3.5	8
6	Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8+ T cells in giant cell arteritis. Rheumatology, 2022, 62, 417-427.	1.9	8
7	Aortic involvement in giant cell arteritis. Joint Bone Spine, 2021, 88, 105045.	1.6	6
8	CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?. Frontiers in Immunology, 2021, 12, 654109.	4.8	6
9	The protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition. Biomedicine and Pharmacotherapy, 2021, 135, 111180.	5.6	5
10	A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKLâ€40/Interleukinâ€13 Receptor α2 Axis. Arthritis and Rheumatology, 2021, 73, 2327-2337.	5.6	27
11	Encouraging data on rituximab in polymyalgia rheumatica. Lancet Rheumatology, The, 2021, , .	3.9	1
12	Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. Journal of Autoimmunity, 2021, 123, 102684.	6.5	20
13	Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment. Journal of Clinical Medicine, 2021, 10, 4958.	2.4	15
14	High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology, 2020, 59, 176-184.	1.9	13
15	Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis. JAMA Internal Medicine, 2020, 180, 1295.	5.1	76
16	Distinct macrophage phenotypes skewed by local granulocyte macrophage colonyâ€stimulating factor (GM SF) and macrophage colonyâ€stimulating factor (M SF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis. Clinical and Translational Immunology, 2020, 9, e1164.	3.8	39
17	Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/CT in giant cell arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 616-623.	3.4	40
18	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56

MARIA SANDOVICI

#	Article	IF	CITATIONS
19	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
20	303. LEUKOCYTE DYNAMICS BEFORE, DURING AND AFTER TREATMENT IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATIC PATIENTS. Rheumatology, 2019, 58, .	1.9	0
21	Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica. Frontiers in Immunology, 2019, 10, 1981.	4.8	40
22	Methotrexate in Giant Cell Arteritis Deserves a Second Chance — A High-dose Methotrexate Trial Is Needed. Journal of Rheumatology, 2019, 46, 453-454.	2.0	8
23	055. HIGH SERUM ANGIOPOIETIN-2 LEVELS IDENTIFY LARGE VESSEL INFLAMMATION IN PATIENTS WITH POLYMYALGIA RHEUMATICA. Rheumatology, 2019, 58, .	1.9	0
24	Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology, 2019, 58, 1383-1392.	1.9	43
25	Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis. Frontiers in Immunology, 2019, 10, 83.	4.8	45
26	FRI0275â€HIGH ANGIOPOIETIN-2 LEVELS ASSOCIATE WITH ARTERIAL INFLAMMATION AND LONG-TERM GLUCOCORTICOID REQUIREMENT IN POLYMYALGIA RHEUMATICA. , 2019, , .		0
27	OP0211â€ULTRASONOGRAPHY CAN POTENTIALLY BE THE FIRST CHOICE OF IMAGING IN SUSPECTED EXTRA-CRANIAL GCA. , 2019, , .		2
28	SAT0228â€LEUKOCYTE DYNAMICS IN GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA PATIENTS BEFO DURING AND AFTER TREATMENT. , 2019, , .	)RE,	0
29	Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?. Arthritis and Rheumatology, 2018, 70, 1366-1376.	5.6	54
30	Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries. Annals of the Rheumatic Diseases, 2018, 77, e16-e16.	0.9	11
31	Towards precision medicine in ANCA-associated vasculitis. Rheumatology, 2018, 57, 1332-1339.	1.9	23
32	Gene therapy with adenovirusâ€delivered indoleamine 2,3â€dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. Journal of Gene Medicine, 2011, 13, 373-381.	2.8	21
33	Towards graft-specific immune suppression: Gene therapy of the transplanted kidneyâ^†. Advanced Drug Delivery Reviews, 2010, 62, 1358-1368.	13.7	10
34	Immune modulation and graft protection by gene therapy in kidney transplantation. European Journal of Pharmacology, 2008, 585, 261-269.	3.5	11
35	Adenovirusâ€mediated interleukinâ€13 gene therapy attenuates acute kidney allograft injury. Journal of Gene Medicine, 2007, 9, 1024-1032.	2.8	17
36	Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica. Frontiers in Medicine, 0, 9, .	2.6	13